OR WAIT null SECS
Phlexglobal, a technology and services provider,has announced that Synairgen, a drug discovery and development company developing therapies for respiratory disease, implemented Phlexglobal’s PhlexTMF SaaS software to support a COVID-19 trial.
After being chosen by Synairgen as the preferred vendor for provision of an eTMF, Phlexglobal implemented its SaaS eTMF software, which includes built-in best practices that aim to improve TMF health, including embedded quality review, event management, wizard-driven completeness, intelligent placeholders, and more. The company’s global team of TMF experts and project managers applied its methodology to go from project kickoff on June 16, 2020, to go-live on July 1, 2020—a total of just 16 days. As part of its ongoing contribution to helping fight the COVID-19 pandemic, Phlexglobal’s corporate commitment is to provide complimentary services.
“Since the outbreak of the COVID-19 pandemic, Phlexglobal has provided extensive support for multiple biopharmaceutical companies developing effective treatments for those who have been impacted by the virus, as well as promising vaccines to prevent its spread,”said John McNeill, Chief Executive Officer of Phlexglobal. “We’re honored to be able to provide critical software and services to help address the most important health crisis facing the world today.”
With 120 home-based and 100 hospital-based patients in the trial, the ease of use of Phlexglobal’s eTMF technology and support services were key factors in Synairgen’s decision.
To read the full release, click here.